Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on January 19, 2021. The Company is an emerging growth company focused on developing drug product candidates, specifically NP-300 (lechlemer) for the symptomatic relief of diarrhea from cholera. The report details a material definitive agreement entered into on January 19, 2021, and updates regarding the Company's Nasdaq listing status.
Key Financial Metrics and Debt
- Debt Issuance: The Company issued a secured promissory note with an aggregate principal amount of $6,220,812.50.
- Proceeds Composition: The principal balance includes $195,812.50 in prepaid interest for the first twelve months and $25,000 to cover transaction expenses.
- Interest Rate: The Note bears interest at 3.25% per annum.
- Maturity Date: January 20, 2025.
- Use of Proceeds: Funding development of lechlemer for the Cholera Indication and general corporate purposes.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for a reporting period.
Material Changes and Agreements
The primary material change is the entry into a Note Purchase Agreement with Streeterville Capital, LLC (an affiliate of Chicago Venture Partners, L.P.). Key terms include:
- TDPRV Participation: If the Company receives and sells a Tropical Disease Priority Review Voucher (TDPRV), the Investor is entitled to a percentage of gross proceeds ranging from 18% down to 1%, depending on the outstanding balance of the Note.
- Optional Prepayment: The Company may prepay the Note at 112.5% of the principal amount beginning six months after closing or upon initiation of human clinical trials, whichever is earlier. Prepayment requires Investor approval after the last patient is enrolled in a pivotal trial.
- Acceleration on Trial Failure: If the Company abandons the trial, fails to start Phase 1 by July 1, 2022, or fails to meet primary endpoints, the Investor may accelerate the Note at 125% of the outstanding balance.
- Security Interest: The Investor received a first priority security interest in existing and future lechlemer technology, subject to third-party consent.
Outlook, Risks, and Other Events
- Nasdaq Listing: The Company previously received notice of a minimum bid price deficiency (below $1.00 for 30 consecutive days). On January 21, 2021, Nasdaq notified the Company that the deficiency was cured and the listing would continue.
- Risks: The debt instrument contains significant risks related to clinical trial milestones. Failure to meet specific trial timelines or endpoints could trigger an acceleration of debt at a penalty rate (125%).
- Unregistered Sales: The Note was sold pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D.
Investor Verification Checklist
- Verify the exact net cash proceeds received after deducting the $25,000 transaction expense and prepaid interest.
- Confirm the status of the third-party consent required to make the security interest in lechlemer technology effective.
- Monitor the July 1, 2022 deadline for the initiation of the Phase 1 clinical trial to avoid debt acceleration.
- Review the specific terms of the TDPRV participation percentage as the Note balance is paid down.
- Check subsequent filings for updates on the Nasdaq minimum bid price compliance.